大脳基底核出血除去における血栓溶解と統合する定位手術 (SOITBE)
大脳基底核出血避難における血栓溶解と統合する定位操作:ランダム化比較試験。
Spontaneous cerebral hemorrhage is one of the main causes of death and disability all over the world, accounting for 20%-30% of all cerebrovascular diseases. Minimally invasive surgery of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term neurological recovery in patients with cerebral hemorrhage. Until now, no standardized practice for minimally invasive surgery of spontaneous cerebral hemorrhage has been established. Hematoma puncture and drainage based on CT scans without precise localization and personalized approach design, which may lead to poor efficacy and high risk of complications. Our hospital has much experience in treating cerebral hemorrhage with stereotactic puncture and aspiration. So we conduct a prospective multicenter randomized controlled clinical trial to determine the therapeutic effects of puncture aspiration plus thrombolysis treatment for the perioperative and long-term recovery of patients with small to moderate hematoma in deep basal ganglia via computerized precision coordinates and personalized approach design.
調査の概要
状態
条件
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310009
- the Second Affiliated Hospital of Zhejiang University School of Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of spontaneous basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a hematoma volume of 10-30 mL calculated by ABC/2 formula and Glasgow Coma Scale score ≥ 9.
- With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic limb muscle strength ≤ grade 3 or NIHSS score ≥ 15 points.
- Hematoma stability shown by a CT scan at least 6 hours after the diagnostic CT (hematoma volume increase < 5 ml by ABC/2 formula).
- Diagnostic CT scan should be obtained within 24 hours after the onset of symptoms. Cases with unclear onset time should be excluded.
- Randomization within 72 hours after diagnostic CT.
- Surgery should be performed within 72 hours after onset.
- SBP <180 mmHg maintained for 6 hours prior to randomization.
- Age between 18-70 years old.
- mRS score ≤ 1 in past medical history.
- Patients who are suitable and willing to be randomized to "puncture aspiration + urokinase" or conservative medical treatment.
Exclusion Criteria:
- Hematoma involves other structures such as the thalamus and midbrain.
- Mass effect or hydrocephalus due to intraventricular hemorrhage.
- Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm, arteriovenous malformation (AVM) and moyamoya disease as well as hemorrhagic transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral hemorrhage.
- Manifestation of early stage cerebral herniation such as ipsilateral pupil changes and midline shift exceeding 1 cm.
- Patients with unsteady hematoma or with progression to intracranial hypertension syndrome.
- Patients with any irreversible coagulopathy or known coagulation disorders; platelet count <100,000; INR > 1.4.
- Patients requiring long-term use of anticoagulants.
- Patients taking dabigatran, apixaban and/or rivaroxaban (or similar drugs of the same category) before symptoms arise.
- Bleeding in other sites, including retroperitoneal, gastrointestinal, genitourinary or respiratory tract bleeding; superficial or skin surface bleeding mainly occurring in the vascular puncture site or transvenous approach (eg. arterial puncture, venous incision, etc. ) or in the recent surgical site.
- May be pregnant in the near future or already pregnant.
- Previously enrolled in this study.
- Participating in other interventional medical research or clinical trials at the same time. Patients enrolled in observational, natural history and/or epidemiological studies (without intervention) are eligible for this trial.
- Patients with an expected survival of less than 6 months.
- Patients with severe co-morbidity (including hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune and/or hematological disorders) which may affect the outcome assessment.
- Patients with mechanical heart valve. Biological valves are acceptable.
- Patients with risk of embolism (including a history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis or subacute bacterial endocarditis). Atrial fibrillation without mitral stenosis is acceptable.
- Investigators believe co-morbidities would be detrimental to the patient when the study begins.
- Patients difficult to follow up or with poor compliance due to various reasons (such as geographical and social factors, drug or alcohol abuse, etc.).
- Patient or his or her legal guardian/representative is unable or unwilling to give the written informed consent.
- Patient is in a condition that is not suitable for "puncture aspiration + urokinase" treatment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:薬物治療による定位手術
|
stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent |
|
偽コンパレータ:Guideline-based standard medical management
|
Guideline-based standard medical management |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Favorable Functional Outcome as Defined by the modified Rankin Scale (mRS) Score
時間枠:180 days
|
Functional independence is defined as achieving a score of 0, 1, or 2 on the mRS. The mRS is a 7-point scale that measures the degree of disability or dependence in the daily activities of patients who have had a stroke. The scale ranges from 0 (no symptoms) to 6 (dead). |
180 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-Cause Mortality
時間枠:180 days
|
Time from randomization to death from any cause up to 180 days. |
180 days
|
|
Barthel Index (BI)
時間枠:180 days
|
Functional status in activities of daily living (ADL) will be assessed using the Barthel Index (BI). The BI score ranges from 0 (completely dependent) to 100 (fully independent). |
180 days
|
|
Glasgow Outcome Scale-Extended (GOS-E) score
時間枠:180 days
|
The GOS-E is an 8-point scale that categorizes global outcomes from Dead (1) to Upper Good Recovery (8). |
180 days
|
|
Residual Hematoma Volume
時間枠:24 hours and one month
|
Absolute volume (in mL) of the hematoma remaining at 24 hours (± 6 hours) and at 1 month (± 7 days) post-intervention |
24 hours and one month
|
|
Length of Initial Hospital Stay
時間枠:one month
|
Total duration (in days) of the index hospitalization from admission to discharge (excluding transfers to other acute care facilities) |
one month
|
|
Total direct medical costs during the index hospitalization
時間枠:one month
|
Total direct healthcare costs related to the index ICH event incurred during the index hospitalization, assessed from a healthcare system perspective |
one month
|
協力者と研究者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2018-222
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。